CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $221.87M, lower than 95% of all stocks globally
- PositionCurrent ratio is 0.87×, lower than 95% of its Biotechnology peers (median 5.64×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
221.87MUSDvs all stocks (USD)
Revenue (TTM)
4.57MCHFvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.57xvs all stocks
52-Week Change
4.59%vs all stocks
Market Capitalization
221.87MUSDvs all stocks (USD)
Enterprise Value
200.65MUSDvs all stocks (USD)
Forward P/E
6.77xvs Biotechnology peers
Price to Sales (TTM)
59.93xvs Biotechnology peers
Price to Book (MRQ)
5.51xvs Biotechnology peers
Enterprise to Revenue
43.86xvs Biotechnology peers
Enterprise to EBITDA
-2.58xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-1321.54%vs Biotechnology peers
Return on Assets (TTM)
-23.06%vs Biotechnology peers
Return on Equity (TTM)
-104.83%vs Biotechnology peers
Revenue (TTM)
4.57MCHFvs all stocks (USD)
Revenue per Share (TTM)
0.0370CHFUpdated Jul 17, 2026Quarterly Revenue Growth
13.00%vs Biotechnology peers
Gross Profit (TTM)
-60.01MCHFvs all stocks (USD)
EBITDA (TTM)
-77.73MCHFvs all stocks (USD)
Net Income (TTM)
-81.83MCHFvs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.03%vs Biotechnology peers
Operating Cash Flow (TTM)
-65.28MCHFvs all stocks (USD)
Levered Free Cash Flow (TTM)
-70.45MCHFvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 17, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.57MCHFFY2025 · Dec 31, 2025Operating Income
-68.86MCHF-84.97M · vs all stocks (USD)
Pre-tax Income
-70.45MCHFFY2025 · Dec 31, 2025Income Tax Expense
0.00CHFFY2025 · Dec 31, 2025Net Income
-70.45MCHFFY2025 · Dec 31, 2025EBIT
-70.26MCHFFY2025 · Dec 31, 2025EBITDA (Income Statement)
-64.50MCHFFY2025 · Dec 31, 2025Research & Development
56.44MCHFFY2025 · Dec 31, 2025Selling, General & Administrative
11.65MCHFFY2025 · Dec 31, 2025Other Operating Expenses
2.73MCHFFY2025 · Dec 31, 2025Non-operating Interest Income
1.86MCHFFY2025 · Dec 31, 2025Non-operating Interest Expense
191.00KCHFFY2025 · Dec 31, 2025EPS (Basic)
-0.7000CHFFY2025 · Dec 31, 2025EPS (Diluted)
-0.7000CHFFY2025 · Dec 31, 2025Basic Shares Outstanding
100.75MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
100.75MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-70.45MCHFFY2025 · Dec 31, 2025Operating Cash Flow
-65.28MCHFFY2025 · Dec 31, 2025Free Cash Flow
-66.17MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.80MCHFFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-70.45MCHFFY2025 · Dec 31, 2025Depreciation & Amortization
2.50MCHFFY2025 · Dec 31, 2025Stock-based Compensation
4.40MCHFFY2025 · Dec 31, 2025Other Non-cash Items
919.00KCHFFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
919.00KCHFFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.57MCHFFY2025 · Dec 31, 2025Capital Expenditures
-885.00KCHFFY2025 · Dec 31, 2025Other Investing Activity
-170.00KCHFFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.05MCHFFY2025 · Dec 31, 2025Long-term Debt Payments
-1.03MCHFFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.02MCHFFY2025 · Dec 31, 2025Shares Outstanding
101.77MSharesUpdated Jul 17, 2026Float Shares
38.75MSharesUpdated Jul 17, 2026Shares Short
3.38MSharesUpdated Jul 17, 2026Short Ratio
10.54daysvs all stocks
Short % of Shares Outstanding
6.92%vs all stocks
% Held by Insiders
37.90%vs all stocks
% Held by Institutions
24.83%vs all stocks
Total Cash (MRQ)
92.43MCHFvs all stocks (USD)
Total Cash per Share (MRQ)
0.7580CHFUpdated Jul 17, 2026Total Debt (MRQ)
5.32MCHFvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1365xvs Biotechnology peers
Current Ratio (MRQ)
0.8680xvs Biotechnology peers
Book Value per Share (MRQ)
0.3956CHFUpdated Jul 17, 2026Total Assets
154.25MCHF190.32M · vs all stocks (USD)
Total Current Assets
96.72MCHFFY2025 · Dec 31, 2025Total Liabilities
109.37MCHFFY2025 · Dec 31, 2025Total Non-current Assets
57.53MCHFFY2025 · Dec 31, 2025Total Non-current Liabilities
14.67MCHFFY2025 · Dec 31, 2025Total Current Liabilities
94.69MCHFFY2025 · Dec 31, 2025Cash & Cash Equivalents
26.80MCHFFY2025 · Dec 31, 2025Other Short-term Investments
64.62MCHFFY2025 · Dec 31, 2025Accounts Payable
2.07MCHFFY2025 · Dec 31, 2025Short-term Debt
852.00KCHFFY2025 · Dec 31, 2025Deferred Revenue
83.71MCHFFY2025 · Dec 31, 2025Long-term Debt
3.69MCHFFY2025 · Dec 31, 2025Common Stock (Book)
2.25MCHFFY2025 · Dec 31, 2025Retained Earnings
-439.02MCHFFY2025 · Dec 31, 2025Total Shareholders' Equity
44.88MCHF55.38M · vs all stocks (USD)
Treasury Stock
218.00KCHFFY2025 · Dec 31, 202552-Week Low
2.02USDUpdated Jul 17, 202652-Week High
4.00USDUpdated Jul 17, 202652-Week Change
4.59%vs all stocks
Beta
1.57xvs all stocks
50-Day MA
2.58USDUpdated Jul 17, 2026200-Day MA
2.98USDUpdated Jul 17, 2026Avg 10-Day Volume
195.69KSharesUpdated Jul 17, 2026Avg 30-Day Volume
279.08KSharesUpdated Jul 17, 2026Diluted EPS (TTM)
-0.8200CHFUpdated Jul 17, 2026Other Income / Expense
-3.26MCHFFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 0.87×, lower than 95% of its Biotechnology peers (median 5.64×)Significant
Current ratio: 0.87Industry median: 5.64Industry P5: 1.06Peers compared: 261
Financial Health
Altman Z-Score -4.47: distress zoneCritical
Altman Z-Score: -4.47
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $221.87M, lower than 95% of all stocks globallySignificant
Market cap (USD): 221,866,389Global P5: 269,387,740.27
Revenue is $4.57M, lower than 95% of all stocks globallySignificant
Revenue (USD): 4,574,524Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Anavex Life Sciences Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Intocell Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Nautilus Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
Eubiologics Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Orchestra BioMed Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Invivyd Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Samyang Biopharmaceuticals Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Protara Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Lineage Cell Therapeutics Inc.
2 interpretationsIntangible ConcentrationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
A2Z Cust2Mate Solutions Corp
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Citra Marga Nusaphala Persada Tbk
1 interpretationIntangible Concentration